William H. Ludlam M.D., Ph.D.
Senior Vice President of Clinical Development & Medical Affairs
Dr. William H. Ludlam, M.D., Ph.D. has been Senior Vice President of Clinical Development & Medical Affairs at Chiasma, Inc. since January 10, 2017. Dr. Ludlam served as Vice President of Clinical Development and Medical Affairs at Chiasma, Inc. since November 15, 2016 until January 10, 2017. Dr. Ludlam served as Vice President of Medical Affairs at Chiasma, Inc. since August 26, 2015 until November 15, 2016. At Chiasma, Dr. Ludlam is responsible for developing strategy around clinical and technical information to support the planned commercial launch of Mycapssa??? for the maintenance treatment of adults with acromegaly and also leads all medical review activities around product education campaign, including its presence at key scientific events. Dr. Ludlam is a highly-regarded academic leader in the pituitary and rare disease space. He spent the last four years at Novartis Pharmaceuticals, where he served as Senior Medical Director for the U.S. Clinical Development and Medical Affairs (USCDMA), Pituitary Disorders, Rare Diseases Franchise. Prior to joining Novartis in 2012, Dr. Ludlam spent 15 years in a number of academic and clinical roles. From 2007 to 2011, he served as Medical Director at the Seattle Pituitary Center within the Neuroscience Institute at the Swedish Medical Center and from 2002 to 2006 as medical director of the Pituitary Unit at the Oregon Health and Science University. Dr. Ludlam helped develop both treatment centers and conducted clinical research for novel treatment options for pituitary disorders while actively treating patients with acromegaly and Cushing's disease, among other conditions. Dr. Ludlam holds an M.D. and Ph.D. from the Albert Einstein College of Medicine and completed his Internal Medicine residency and Endocrinology fellowship at the Oregon Health & Sciences University, where he also conducted research at the Vollum Institute under Dr. Richard H. Goodman.